HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Lumos Pharma (NASDAQ:LUMO) and maintained a price target of $28.
September 06, 2023 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lumos Pharma's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $28 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a maintained price target of $28 by HC Wainwright & Co. suggests a positive outlook for Lumos Pharma, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100